PE20071101A1 - Polipeptidos y anticuerpos - Google Patents
Polipeptidos y anticuerposInfo
- Publication number
- PE20071101A1 PE20071101A1 PE2006001018A PE2006001018A PE20071101A1 PE 20071101 A1 PE20071101 A1 PE 20071101A1 PE 2006001018 A PE2006001018 A PE 2006001018A PE 2006001018 A PE2006001018 A PE 2006001018A PE 20071101 A1 PE20071101 A1 PE 20071101A1
- Authority
- PE
- Peru
- Prior art keywords
- seq
- cdr
- polypeptide
- antibody
- complementary determining
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
SE REFIERE A UN ANTICUERPO QUE SE UNE AL RECEPTOR 2 (TR-2) DEL LIGANDO QUE INDUCE EL FACTOR DE NECROSIS TUMORAL (TNF)-RELACIONADO CON APOPTOSIS (TRAIL) QUE COMPRENDE: i) UN PRIMER POLIPEPTIDO QUE FORMA PARTE DE LA REGION VARIABLE DE LA CADENA PESADA Y COMPRENDE UNA REGION DETERMINANTE COMPLEMENTARIA (CDR) SELECCIONADA DE CDR1a, CDR2a Y CDR3a, DONDE CADA UNO TIENE UNA SECUENCIA DETERMINADA DE AMINOACIDOS EN LA SEC ID Nº 2, SEC ID Nº 4, SEC ID Nº 6, SEC ID Nº 8, ENTRE OTROS; ii) UN SEGUNDO POLIPEPTIDO QUE FORMA PARTE DE LA REGION VARIABLE DE LA CADENA LIGERA Y COMPRENDE UNA REGION DETERMINANTE COMPLEMENTARIA (CDR) SELECCIONADA DE CDR1b, CDR2b Y CDR3b, DONDE CADA UNO TIENE UNA SECUENCIA DETERMINADA DE AMINOACIDOS EN LA SEC ID Nº 36, SEC ID Nº 38, SEC ID Nº 40, SEC ID Nº 42, ENTRE OTROS. DICHO ANTICUERPO TIENE MARCAS DETECTABLES ENZIMATICA, FLUORESCENTE, QUIMIOLUMINISCENTE O RADIACTIVA SIENDO UTIL EN EL TRATAMIENTO DE CANCER DE PULMON, LEUCEMIA, CARCINOMA GASTRICO
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US71347805P | 2005-08-31 | 2005-08-31 | |
US71343305P | 2005-08-31 | 2005-08-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20071101A1 true PE20071101A1 (es) | 2007-12-21 |
Family
ID=37546951
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2006001018A PE20071101A1 (es) | 2005-08-31 | 2006-08-23 | Polipeptidos y anticuerpos |
Country Status (20)
Country | Link |
---|---|
US (3) | US7521048B2 (es) |
EP (1) | EP1922337B1 (es) |
JP (2) | JP2009505676A (es) |
KR (1) | KR101359152B1 (es) |
AR (1) | AR058804A1 (es) |
AU (1) | AU2006284884B8 (es) |
BR (1) | BRPI0615218A2 (es) |
CA (1) | CA2620470C (es) |
CR (1) | CR9796A (es) |
EA (1) | EA014295B1 (es) |
GT (1) | GT200600389A (es) |
IL (1) | IL189670A (es) |
MX (1) | MX2008002735A (es) |
MY (1) | MY147257A (es) |
NO (1) | NO20080980L (es) |
NZ (1) | NZ566394A (es) |
PE (1) | PE20071101A1 (es) |
TW (1) | TWI398448B (es) |
UY (1) | UY29770A1 (es) |
WO (1) | WO2007027713A2 (es) |
Families Citing this family (138)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004003144A2 (en) * | 2002-07-01 | 2004-01-08 | Human Genome Sciences, Inc. | Antibodies that specifically bind to reg iv |
AR045563A1 (es) | 2003-09-10 | 2005-11-02 | Warner Lambert Co | Anticuerpos dirigidos a m-csf |
US8029783B2 (en) * | 2005-02-02 | 2011-10-04 | Genentech, Inc. | DR5 antibodies and articles of manufacture containing same |
PE20071101A1 (es) * | 2005-08-31 | 2007-12-21 | Amgen Inc | Polipeptidos y anticuerpos |
WO2008143733A2 (en) * | 2007-03-02 | 2008-11-27 | Dohney Eye Institute | Biocompatible implants and methods of making and attaching the same |
US20080305320A1 (en) * | 2007-03-02 | 2008-12-11 | Lucien Laude | Nanoscale surface activation of silicone via laser processing |
US20110097318A1 (en) * | 2007-08-31 | 2011-04-28 | Amgen Inc. | Solid-State Protein Formulation |
JO2913B1 (en) | 2008-02-20 | 2015-09-15 | امجين إنك, | Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses |
CA2755336C (en) | 2009-03-20 | 2015-07-14 | Amgen Inc. | Carrier immunoglobulins and uses thereof |
EP2415781A4 (en) * | 2009-04-03 | 2012-10-17 | Inst Basic Med Sciences Pla | ANTIGENIC DETERMINANTS RECOGNIZED BY A MONOCLONAL ANTIBODY AD5-10 HUMAN DR5 HUMAN DEATH RECEPTOR, DERIVATIVES AND USES THEREOF |
US8877199B2 (en) | 2009-05-15 | 2014-11-04 | The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | B cell surface reactive antibodies |
US9662271B2 (en) | 2009-10-23 | 2017-05-30 | Amgen Inc. | Vial adapter and system |
US9238069B2 (en) | 2009-12-16 | 2016-01-19 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Method of sensitizing cancer cells to the cytotoxic effects of death receptor ligands in cancer treatment |
EP2534170B1 (en) | 2010-02-12 | 2017-04-19 | Pharmascience Inc. | Iap bir domain binding compounds |
SI2575935T2 (sl) | 2010-06-07 | 2023-12-29 | Amgen Inc. | Naprava za dajanje zdravila |
EA201370076A1 (ru) | 2010-09-22 | 2013-08-30 | Амген Инк. | Иммуноглобулины-переносчики и их применение |
BR112013007293A2 (pt) | 2010-10-05 | 2016-06-14 | Hoffmann La Roche | anticorpos contra a tweak de seres humanos e suas utilizações |
NZ610153A (en) | 2010-10-29 | 2014-07-25 | Daiichi Sankyo Co Ltd | Novel anti-dr5 antibody |
EP2681238A2 (en) | 2011-02-28 | 2014-01-08 | Istituto di Ricovero E Cura A Carattere Scientifico Materno-Infantile Burlo Garofolo- Ospedale di Alta Specializzazione E di Rilievo | Apoptosis-inducing molecules and uses therefor |
AU2012236573B2 (en) | 2011-03-31 | 2016-06-02 | Amgen Inc. | Vial adapter and system |
HUE042822T2 (hu) | 2011-04-20 | 2019-07-29 | Amgen Inc | Automata befecskendezõ szerkezet |
EP2731965A4 (en) | 2011-07-12 | 2015-06-03 | Xbiotech Inc | IDENTIFICATION OF AFFINITY-TREATED HUMAN ANTIBODIES |
IL301153B2 (en) | 2011-10-14 | 2024-05-01 | Amgen Inc | Syringe and assembly method |
CN103945867B (zh) | 2011-10-27 | 2018-01-02 | Nkt治疗公司 | 针对iNKT的人类化抗体 |
AU2012328173B2 (en) * | 2011-10-28 | 2016-04-21 | Janssen Biotech, Inc. | Therapeutic agents and uses thereof |
CA2867631C (en) * | 2012-03-28 | 2019-06-11 | Amgen Inc. | Dr5 receptor agonist combinations |
CN105050618B (zh) | 2012-06-21 | 2018-11-16 | 索伦托治疗有限公司 | 与c-Met结合的抗原结合蛋白 |
CA3206182A1 (en) | 2012-11-21 | 2014-05-30 | Amgen Inc. | Drug delivery device including insertion member and reservoir |
UY35148A (es) | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
US9708375B2 (en) | 2013-03-15 | 2017-07-18 | Amgen Inc. | Inhibitory polypeptides specific to WNT inhibitors |
EP2968775B1 (en) | 2013-03-15 | 2019-12-18 | Amgen Inc. | Drug cassette, autoinjector, and autoinjector system |
JP6336564B2 (ja) | 2013-03-15 | 2018-06-06 | アムゲン・インコーポレーテッド | 薬物カセット、自動注入器、および自動注入器システム |
IL292270B2 (en) | 2013-03-22 | 2024-04-01 | Amgen Inc | Injector and assembly method |
UA118028C2 (uk) | 2013-04-03 | 2018-11-12 | Рош Глікарт Аг | Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування |
JP6668241B2 (ja) | 2013-09-05 | 2020-03-18 | アムジエン・インコーポレーテツド | 予測可能で、一貫性のある、且つ再現可能な糖型特性を示すFc含有分子 |
MX2016005312A (es) | 2013-10-24 | 2016-08-11 | Amgen Inc | Inyector y metodo de montaje. |
EP3501575B1 (en) | 2013-10-24 | 2021-12-01 | Amgen Inc. | Drug delivery system with temperature-sensitive-control |
CN112079923A (zh) * | 2013-12-26 | 2020-12-15 | 田边三菱制药株式会社 | 人抗il-33中和单克隆抗体 |
US10994112B2 (en) | 2014-02-05 | 2021-05-04 | Amgen Inc. | Drug delivery system with electromagnetic field generator |
EP3785749A1 (en) | 2014-05-07 | 2021-03-03 | Amgen Inc. | Autoinjector with shock reducing elements |
WO2015175861A1 (en) | 2014-05-16 | 2015-11-19 | Amgen Inc. | Assay for detecting th1 and th2 cell populations |
SG11201609162SA (en) * | 2014-05-16 | 2016-12-29 | Ablynx Nv | Improved immunoglobulin variable domains |
CN106470717B (zh) | 2014-06-03 | 2020-09-11 | 安姆根有限公司 | 药物递送系统和使用方法 |
EP3943135A3 (en) | 2014-10-14 | 2022-06-29 | Amgen Inc. | Drug injection device with visual and audible indicators |
UY36449A (es) | 2014-12-19 | 2016-07-29 | Novartis Ag | Composiciones y métodos para anticuerpos dirigidos a bmp6 |
US11357916B2 (en) | 2014-12-19 | 2022-06-14 | Amgen Inc. | Drug delivery device with live button or user interface field |
EP3848072A1 (en) | 2014-12-19 | 2021-07-14 | Amgen Inc. | Drug delivery device with proximity sensor |
AU2016209324B2 (en) | 2015-01-20 | 2020-02-27 | Igm Biosciences, Inc. | Tumor necrosis factor (TNF) superfamily receptor binding molecules and uses thereof |
CA2976935C (en) | 2015-02-17 | 2020-03-10 | Amgen Inc. | Drug delivery device with vacuum assisted securement and/or feedback |
JP2018512184A (ja) | 2015-02-27 | 2018-05-17 | アムジエン・インコーポレーテツド | 針ガードの移動に対する抵抗力の閾値が調整可能な針ガード機構を備えた薬物送達装置 |
WO2017039786A1 (en) | 2015-09-02 | 2017-03-09 | Amgen Inc. | Syringe assembly adapter for a syringe |
JP2019501151A (ja) * | 2015-12-01 | 2019-01-17 | ゲンマブ ビー.ブイ. | 抗デスレセプター抗体およびその使用方法 |
JP7082568B2 (ja) | 2015-12-09 | 2022-06-08 | アムジエン・インコーポレーテツド | 信号伝達キャップ付き自動注射器 |
WO2017120178A1 (en) | 2016-01-06 | 2017-07-13 | Amgen Inc. | Auto-injector with signaling electronics |
US10849912B2 (en) | 2016-02-09 | 2020-12-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Method of sensitizing cancer cells to the cytotoxic effects of apoptosis inducing ligands in cancer treatment |
US11200298B2 (en) | 2016-03-15 | 2021-12-14 | Amgen Inc. | Reducing probability of glass breakage in drug delivery devices |
US11541168B2 (en) | 2016-04-29 | 2023-01-03 | Amgen Inc. | Drug delivery device with messaging label |
WO2017192287A1 (en) | 2016-05-02 | 2017-11-09 | Amgen Inc. | Syringe adapter and guide for filling an on-body injector |
CA3018426A1 (en) | 2016-05-13 | 2017-11-16 | Amgen Inc. | Vial sleeve assembly |
US11238150B2 (en) | 2016-05-16 | 2022-02-01 | Amgen Inc. | Data encryption in medical devices with limited computational capability |
WO2017209899A1 (en) | 2016-06-03 | 2017-12-07 | Amgen Inc. | Impact testing apparatuses and methods for drug delivery devices |
AU2017283787B2 (en) | 2016-06-15 | 2020-09-17 | Novartis Ag | Methods for treating disease using inhibitors of bone morphogenetic protein 6 (BMP6) |
US11285266B2 (en) | 2016-07-01 | 2022-03-29 | Amgen Inc. | Drug delivery device having minimized risk of component fracture upon impact events |
WO2018034784A1 (en) | 2016-08-17 | 2018-02-22 | Amgen Inc. | Drug delivery device with placement detection |
US20200261643A1 (en) | 2016-10-25 | 2020-08-20 | Amgen Inc. | On-body injector |
AU2017359439A1 (en) | 2016-11-08 | 2019-05-23 | Regeneron Pharmaceuticals, Inc. | Antigen-binding proteins that antagonize leptin receptor |
WO2018089508A2 (en) * | 2016-11-08 | 2018-05-17 | Ablexis, Llc | Anti-cd47 antibodies |
MX2019008432A (es) | 2017-01-17 | 2019-11-18 | Amgen Inc | Dispositivos de inyeccion y metodos relacionados de uso y ensamblaje. |
CN110944651A (zh) | 2017-02-08 | 2020-03-31 | 蜻蜓疗法股份有限公司 | 用于自然杀伤细胞激活的多特异性结合蛋白及其治疗癌症的治疗性用途 |
US20200095327A1 (en) * | 2017-02-08 | 2020-03-26 | Dragonfly Therapeutics, Inc. | Antibody heavy chain variable domains targeting the nkg2d receptor |
KR20240101717A (ko) | 2017-02-10 | 2024-07-02 | 젠맵 비. 브이 | 폴리펩티드 변이체 및 그의 용도 |
EP3582825A1 (en) | 2017-02-17 | 2019-12-25 | Amgen Inc. | Drug delivery device with sterile fluid flowpath and related method of assembly |
AU2018221351B2 (en) | 2017-02-17 | 2023-02-23 | Amgen Inc. | Insertion mechanism for drug delivery device |
ES2955074T3 (es) | 2017-02-20 | 2023-11-28 | Dragonfly Therapeutics Inc | Proteínas que se unen a HER2, NKG2D Y CD16 |
JP2020508803A (ja) | 2017-03-06 | 2020-03-26 | アムジエン・インコーポレーテツド | 作動防止特徴部を備える薬物送達デバイス |
EP3592402A1 (en) | 2017-03-07 | 2020-01-15 | Amgen Inc. | Needle insertion by overpressure |
AU2018230486B2 (en) | 2017-03-09 | 2023-05-11 | Amgen Inc. | Insertion mechanism for drug delivery device |
WO2018170099A1 (en) | 2017-03-14 | 2018-09-20 | Amgen Inc. | Control of total afucosylated glycoforms of antibodies produced in cell culture |
KR102517342B1 (ko) | 2017-03-28 | 2023-03-31 | 암겐 인코포레이티드 | 플런저 로드 및 주사기 조립 시스템 및 방법 |
TWI796329B (zh) | 2017-04-07 | 2023-03-21 | 美商默沙東有限責任公司 | 抗-ilt4抗體及抗原結合片段 |
EP3635005A1 (en) | 2017-06-07 | 2020-04-15 | Genmab B.V. | Therapeutic antibodies based on mutated igg hexamers |
US11590294B2 (en) | 2017-06-08 | 2023-02-28 | Amgen Inc. | Syringe assembly for a drug delivery device and method of assembly |
JP7200134B2 (ja) | 2017-06-08 | 2023-01-06 | アムジエン・インコーポレーテツド | トルク駆動式薬物送達デバイス |
EP3641857A1 (en) | 2017-06-22 | 2020-04-29 | Amgen Inc. | Device activation impact/shock reduction |
US11395880B2 (en) | 2017-06-23 | 2022-07-26 | Amgen Inc. | Electronic drug delivery device |
WO2019014014A1 (en) | 2017-07-14 | 2019-01-17 | Amgen Inc. | NEEDLE INSERTION-RETRACTING SYSTEM HAVING DOUBLE TORSION SPRING SYSTEM |
IL271173B2 (en) | 2017-07-21 | 2024-04-01 | Amgen Inc | Gas permeable sealing element for drug container and methods of assembly |
EP3658206A1 (en) | 2017-07-25 | 2020-06-03 | Amgen Inc. | Drug delivery device with container access system and related method of assembly |
JP2020528296A (ja) | 2017-07-25 | 2020-09-24 | アムジエン・インコーポレーテツド | ギヤモジュールを有する薬物送達デバイス及び関連する組立方法 |
WO2019032482A2 (en) | 2017-08-09 | 2019-02-14 | Amgen Inc. | HYDRAULIC-PNEUMATIC PRESSURE CHAMBER DELIVERY SYSTEM |
WO2019036181A1 (en) | 2017-08-18 | 2019-02-21 | Amgen Inc. | BODY INJECTOR WITH STERILE ADHESIVE PATCH |
US11103636B2 (en) | 2017-08-22 | 2021-08-31 | Amgen Inc. | Needle insertion mechanism for drug delivery device |
US11759565B2 (en) | 2017-10-04 | 2023-09-19 | Amgen Inc. | Flow adapter for drug delivery device |
EP3691716B1 (en) | 2017-10-06 | 2023-11-29 | Amgen Inc. | Drug delivery device with interlock assembly and related method of assembly |
EP3694578A1 (en) | 2017-10-09 | 2020-08-19 | Amgen Inc. | Drug delivery device with drive assembly and related method of assembly |
EP3703779A1 (en) | 2017-11-03 | 2020-09-09 | Amgen Inc. | Systems and approaches for sterilizing a drug delivery device |
EP3706830B1 (en) | 2017-11-06 | 2024-08-07 | Amgen Inc. | Drug delivery device with placement and flow sensing |
EP3707075A1 (en) | 2017-11-06 | 2020-09-16 | Amgen Inc. | Fill-finish assemblies and related methods |
JP7247174B2 (ja) | 2017-11-10 | 2023-03-28 | アムジエン・インコーポレーテツド | 薬物送達デバイスのプランジャ |
MA50903A (fr) | 2017-11-16 | 2021-05-12 | Amgen Inc | Auto-injecteur avec détection de décrochage et de point d'extrémité |
CA3079540A1 (en) | 2017-11-16 | 2019-05-23 | Amgen Inc. | Door latch mechanism for drug delivery device |
CN107909501B (zh) * | 2017-12-05 | 2020-12-01 | 创新先进技术有限公司 | 气味与行为的关联方法、气味社交方法及装置 |
JP2021509021A (ja) | 2017-12-18 | 2021-03-18 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | レプチン受容体および/またはgp130に結合する二重特異性抗原結合分子、ならびにその使用方法 |
PE20210708A1 (es) | 2018-02-01 | 2021-04-16 | Pfizer | Anticuerpos especificos para cd70 y sus usos |
EP3749346B1 (en) | 2018-02-08 | 2024-07-10 | Dragonfly Therapeutics, Inc. | Antibody variable domain combinations targeting the nkg2d receptor |
EP3759229A4 (en) * | 2018-02-26 | 2021-12-29 | IGM Biosciences Inc. | Use of a multimeric anti-dr5 binding molecule in combination with a chemotherapeutic agent for treating cancer |
US12018045B2 (en) | 2018-03-06 | 2024-06-25 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | 17-beta-hydroxywithanolides and use thereof in treating cancer |
SG11202009216YA (en) | 2018-03-26 | 2020-10-29 | Amgen Inc | Total afucosylated glycoforms of antibodies produced in cell culture |
AU2019249273A1 (en) | 2018-04-06 | 2020-10-15 | Regeneron Pharmaceuticals, Inc. | Methods of treatment using a leptin receptor agonist antibody |
MA52772A (fr) | 2018-05-24 | 2021-04-14 | Janssen Biotech Inc | Anticorps anti-tmeff2 monospécifiques et multispécifiques et leurs utilisations |
US10835685B2 (en) | 2018-05-30 | 2020-11-17 | Amgen Inc. | Thermal spring release mechanism for a drug delivery device |
US11083840B2 (en) | 2018-06-01 | 2021-08-10 | Amgen Inc. | Modular fluid path assemblies for drug delivery devices |
US11939370B2 (en) * | 2018-07-12 | 2024-03-26 | Vanderbilt University | Pan-ebola virus neutralizing human antibodies and methods of use therefor |
WO2020023220A1 (en) | 2018-07-24 | 2020-01-30 | Amgen Inc. | Hybrid drug delivery devices with tacky skin attachment portion and related method of preparation |
MX2021000748A (es) | 2018-07-24 | 2021-03-26 | Amgen Inc | Dispositivos de suministro para administrar farmacos. |
WO2020023336A1 (en) | 2018-07-24 | 2020-01-30 | Amgen Inc. | Hybrid drug delivery devices with grip portion |
EP3826699A1 (en) | 2018-07-24 | 2021-06-02 | Amgen Inc. | Delivery devices for administering drugs |
MA53320A (fr) | 2018-07-31 | 2021-11-03 | Amgen Inc | Ensemble de trajet de fluide pour dispositif d'administration de médicament |
US20210346601A1 (en) | 2018-09-24 | 2021-11-11 | Amgen Inc. | Interventional dosing systems and methods |
US12042642B2 (en) | 2018-09-28 | 2024-07-23 | Amgen Inc. | Muscle wire escapement activation assembly for a drug delivery device |
TW202027806A (zh) | 2018-10-02 | 2020-08-01 | 美商安進公司 | 具有內部力傳遞的用於藥物遞送之注射系統 |
MX2021003491A (es) | 2018-10-05 | 2021-06-18 | Amgen Inc | Dispositivo de administracion de farmacos con indicador de dosis. |
CN112689523A (zh) | 2018-10-15 | 2021-04-20 | 安进公司 | 用于药物递送装置的平台组装方法 |
MX2021004219A (es) | 2018-10-15 | 2021-05-27 | Amgen Inc | Dispositivo de administracion de farmacos con mecanismo de amortiguacion. |
AU2019370159A1 (en) | 2018-11-01 | 2021-04-22 | Amgen Inc. | Drug delivery devices with partial drug delivery member retraction |
TWI831847B (zh) | 2018-11-01 | 2024-02-11 | 美商安進公司 | 部分針頭縮回之藥物遞送裝置及其操作方法 |
US11213620B2 (en) | 2018-11-01 | 2022-01-04 | Amgen Inc. | Drug delivery devices with partial drug delivery member retraction |
JP7510952B2 (ja) | 2019-04-24 | 2024-07-04 | アムジエン・インコーポレーテツド | シリンジ滅菌確認アセンブリ及び方法 |
JP2022545227A (ja) | 2019-08-23 | 2022-10-26 | アムジエン・インコーポレーテツド | 構成可能な針シールド係合構成要素を備えた薬物送達デバイス及び関連方法 |
MX2022003461A (es) | 2019-09-26 | 2022-04-19 | Amgen Inc | Metodos de produccion de composiciones de anticuerpos. |
US20230273126A1 (en) | 2020-06-04 | 2023-08-31 | Amgen Inc. | Assessment of cleaning procedures of a biotherapeutic manufacturing process |
EP4229080A1 (en) | 2020-10-15 | 2023-08-23 | Amgen Inc. | Relative unpaired glycans in antibody production methods |
CN112661845B (zh) * | 2020-12-25 | 2022-06-21 | 暨南大学 | 与cxcr4结合的亲和力成熟结合蛋白及其应用 |
CN112521500B (zh) * | 2020-12-25 | 2022-06-24 | 暨南大学 | 与cxcr4结合的亲和力成熟结合蛋白及应用 |
WO2022246055A1 (en) | 2021-05-21 | 2022-11-24 | Amgen Inc. | Method of optimizing a filling recipe for a drug container |
AR126089A1 (es) | 2021-06-07 | 2023-09-13 | Amgen Inc | Uso de fucosidasa para controlar el nivel de afucosilación de proteínas glucosiladas |
MX2024003852A (es) | 2021-10-05 | 2024-05-24 | Amgen Inc | Unión al receptor fc-gamma y contenido de glucanos. |
WO2023215725A1 (en) | 2022-05-02 | 2023-11-09 | Fred Hutchinson Cancer Center | Compositions and methods for cellular immunotherapy |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2090126C (en) | 1990-08-02 | 2002-10-22 | John W. Schrader | Methods for the production of proteins with a desired function |
NZ311982A (en) | 1995-06-29 | 1999-08-30 | Immunex Corp | Tnf related apoptosis inducing ligand (trail), a method for producing them and associated antibodies |
US6433147B1 (en) | 1997-01-28 | 2002-08-13 | Human Genome Sciences, Inc. | Death domain containing receptor-4 |
DK1012274T4 (da) | 1997-01-28 | 2011-07-25 | Human Genome Sciences Inc | Dødsdomæneholdig receptor-4 (DR4: dødsreceptor 4), medlem af TNF-receptorsuperfamilien og som binder til TRAIL (Apo-2L) |
US20010010924A1 (en) | 1997-03-14 | 2001-08-02 | Keith Charles Deen | Tumor necrosis factor related receptor, tr6 polynecleotides |
US6313269B1 (en) | 1997-03-14 | 2001-11-06 | Smithkline Beecham Corporation | Tumor necrosis factor related receptor, TR6 |
US7803615B1 (en) | 1997-03-17 | 2010-09-28 | Human Genome Sciences, Inc. | Death domain containing receptor 5 |
US6872568B1 (en) | 1997-03-17 | 2005-03-29 | Human Genome Sciences, Inc. | Death domain containing receptor 5 antibodies |
WO1998046643A1 (en) | 1997-04-16 | 1998-10-22 | Millennium Biotherapeutics, Inc. | TUMOR NECROSIS FACTOR RECEPTOR RELATED PROTEINS TANGO-63d AND TANGO-63e |
US6342369B1 (en) | 1997-05-15 | 2002-01-29 | Genentech, Inc. | Apo-2-receptor |
PT981618E (pt) | 1997-05-15 | 2007-11-23 | Genentech Inc | ''anticorpo anti-apo-2'' |
EP1032661A1 (en) | 1997-06-18 | 2000-09-06 | Genentech, Inc. | Apo-2DcR |
AU8400398A (en) | 1997-07-11 | 1999-02-08 | Trustees Of The University Of Pennsylvania, The | Nucleic acid encoding a novel chemotherapy-induced protein, and methods of use |
US6417328B2 (en) | 1997-08-15 | 2002-07-09 | Thomas Jefferson Univeristy | Trail receptors, nucleic acids encoding the same, and methods of use thereof |
AU9376498A (en) | 1997-09-05 | 1999-03-22 | University Of Washington | Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents |
CA2301173C (en) | 1997-09-12 | 2015-04-14 | Biogen, Inc. | Cysteine rich receptors-train |
CA2328498A1 (en) | 1998-06-12 | 1999-12-16 | Genentech, Inc. | Monoclonal antibodies, cross-reactive antibodies and method for producing the same____________________________________ |
EP1196191A4 (en) | 1999-05-04 | 2004-03-24 | Human Genome Sciences Inc | DEATH DOMAIN CONTAINING RECEPTOR 5 |
CA2384762A1 (en) | 1999-09-15 | 2001-03-22 | Genentech, Inc. | Apo-2 receptor antibodies |
TWI318983B (en) * | 2000-05-02 | 2010-01-01 | Uab Research Foundation | An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof |
KR20020056565A (ko) | 2000-12-29 | 2002-07-10 | 황규언 | 인간유래 세포 소멸 인자와 그 수용체의 결합체인TRAIL-sDR5 결합체의 결정화에 의한 3차원 구조및 TRAIL 결실 돌연변이 단백질 |
AU2002361784A1 (en) * | 2001-12-20 | 2003-07-09 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to trail receptors |
US7135174B2 (en) * | 2002-01-07 | 2006-11-14 | Amgen Fremont, Inc. | Antibodies directed to PDGFD and uses thereof |
US20040141969A1 (en) * | 2002-09-16 | 2004-07-22 | Juergen Floege | Method for the treatment of nephritis using anti-PDGF-DD antibodies |
DE602004025101D1 (de) * | 2003-05-31 | 2010-03-04 | Micromet Ag | Humane anti-humane cd3-bindungsmoleküle |
KR20070010046A (ko) * | 2004-04-06 | 2007-01-19 | 제넨테크, 인크. | Dr5 항체 및 그의 용도 |
US7865356B2 (en) * | 2004-07-15 | 2011-01-04 | Robert Bosch Gmbh | Method and apparatus for providing proper or partial proper name recognition |
EP1807451A2 (en) * | 2004-08-03 | 2007-07-18 | Dyax Corporation | Hk1-binding proteins |
PE20071101A1 (es) * | 2005-08-31 | 2007-12-21 | Amgen Inc | Polipeptidos y anticuerpos |
AU2006332713B2 (en) * | 2005-12-30 | 2013-01-17 | Takeda Pharmaceutical Company Limited | Metalloproteinase binding proteins |
-
2006
- 2006-08-23 PE PE2006001018A patent/PE20071101A1/es not_active Application Discontinuation
- 2006-08-28 JP JP2008529202A patent/JP2009505676A/ja active Pending
- 2006-08-28 CA CA2620470A patent/CA2620470C/en active Active
- 2006-08-28 EP EP20060802591 patent/EP1922337B1/en active Active
- 2006-08-28 MY MYPI20080413A patent/MY147257A/en unknown
- 2006-08-28 US US11/512,051 patent/US7521048B2/en active Active
- 2006-08-28 WO PCT/US2006/033763 patent/WO2007027713A2/en active Application Filing
- 2006-08-28 AU AU2006284884A patent/AU2006284884B8/en active Active
- 2006-08-28 EA EA200800696A patent/EA014295B1/ru not_active IP Right Cessation
- 2006-08-28 KR KR1020087006831A patent/KR101359152B1/ko not_active IP Right Cessation
- 2006-08-28 MX MX2008002735A patent/MX2008002735A/es active IP Right Grant
- 2006-08-28 NZ NZ566394A patent/NZ566394A/en not_active IP Right Cessation
- 2006-08-28 GT GT200600389A patent/GT200600389A/es unknown
- 2006-08-28 BR BRPI0615218-0A patent/BRPI0615218A2/pt not_active IP Right Cessation
- 2006-08-29 TW TW095131655A patent/TWI398448B/zh not_active IP Right Cessation
- 2006-08-29 UY UY29770A patent/UY29770A1/es not_active Application Discontinuation
- 2006-08-30 AR ARP060103787A patent/AR058804A1/es not_active Application Discontinuation
-
2008
- 2008-02-21 IL IL189670A patent/IL189670A/en not_active IP Right Cessation
- 2008-02-25 NO NO20080980A patent/NO20080980L/no not_active Application Discontinuation
- 2008-03-06 CR CR9796A patent/CR9796A/es unknown
-
2009
- 2009-04-02 US US12/417,438 patent/US20090226438A1/en not_active Abandoned
-
2012
- 2012-04-27 JP JP2012103377A patent/JP2012188428A/ja active Pending
- 2012-09-07 US US13/607,384 patent/US20130101589A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU2006284884A8 (en) | 2011-06-09 |
AU2006284884B2 (en) | 2011-02-17 |
NO20080980L (no) | 2008-05-29 |
TW200740847A (en) | 2007-11-01 |
MY147257A (en) | 2012-11-14 |
EP1922337B1 (en) | 2015-05-06 |
EP1922337A2 (en) | 2008-05-21 |
CR9796A (es) | 2008-07-22 |
US20090226438A1 (en) | 2009-09-10 |
IL189670A0 (en) | 2008-06-05 |
KR20080059379A (ko) | 2008-06-27 |
AU2006284884A1 (en) | 2007-03-08 |
US20070179086A1 (en) | 2007-08-02 |
AR058804A1 (es) | 2008-02-27 |
CA2620470C (en) | 2016-09-27 |
EA200800696A1 (ru) | 2008-10-30 |
US7521048B2 (en) | 2009-04-21 |
IL189670A (en) | 2012-07-31 |
KR101359152B1 (ko) | 2014-02-19 |
NZ566394A (en) | 2012-02-24 |
MX2008002735A (es) | 2008-03-26 |
WO2007027713A2 (en) | 2007-03-08 |
US20130101589A1 (en) | 2013-04-25 |
GT200600389A (es) | 2007-05-04 |
JP2012188428A (ja) | 2012-10-04 |
JP2009505676A (ja) | 2009-02-12 |
WO2007027713A3 (en) | 2007-06-28 |
UY29770A1 (es) | 2007-03-30 |
AU2006284884B8 (en) | 2011-06-09 |
CA2620470A1 (en) | 2007-03-08 |
TWI398448B (zh) | 2013-06-11 |
EA014295B1 (ru) | 2010-10-29 |
BRPI0615218A2 (pt) | 2013-01-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20071101A1 (es) | Polipeptidos y anticuerpos | |
NZ596317A (en) | Antibodies directed to her-3 and uses thereof | |
UY28641A1 (es) | Anticuerpos | |
ES2525477T3 (es) | Anticuerpos anti-factor D humanizados | |
PE20091004A1 (es) | Proteinas de union a antigenos c-fms humanos | |
WO2006113546A3 (en) | Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers | |
Chandrawati et al. | Controlled assembly of peptide-functionalized gold nanoparticles for label-free detection of blood coagulation Factor XIII activity | |
WO2020142659A3 (en) | Multi-specific protein molecules and uses thereof | |
PE20070374A1 (es) | ANTICUERPOS ANTI-MAdCAM | |
JP2016516789A5 (es) | ||
EA200701597A1 (ru) | Димерные ингибиторы ингибиторов белков апоптоза (iap) | |
NO20074740L (no) | Fremgangsmater for anvendelse av dodsreseptoragonister og EGFR-inhibitorer | |
MX2010004910A (es) | Anticuerpos monoclonales recombinantes y antigenos correspondientes para canceres colonico y pancreatico. | |
PE20100054A1 (es) | Inmunoglobulina con dominio variable dual | |
NO20071790L (no) | Fremgangsmater for anvendelse av dodsreseptorligander og CD20-antistoffer | |
DE69033842D1 (de) | Äusserliche domäne von c-erbb-2:gp75 | |
AR033157A1 (es) | Uso de proteina alfa de activacion de los fibroblastos ("fapaalfa")bibh1 en el tratamiento del cancer | |
NO20071789L (no) | Fremgangsmate for anvendelse av dodsreseptorligander og CD20-antistoffer | |
AR080663A1 (es) | Proteinas de union especificas y sus usos | |
DE602006018424D1 (de) | Peptide zum nachweis von ehrlichia ewingii antikörper | |
AR110755A1 (es) | Anticuerpos dirigidos a hueso | |
JP2012505659A5 (es) | ||
ES2145084T3 (es) | Inmunoensayo sobre una superficie solida prebloqueada. | |
WO2002072008A3 (en) | Method for treating cancer using a33 specific antibodies and chemotherapeutic agents | |
ATE426155T1 (de) | Sensoranordnung zur lumineszenzmessung |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |